PMPeter John Morrison

Peter John Morrison

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Peter John Morrison has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Oral Dimethyl Fumarate Targets HCA2-Expressing Skin Cells in the Imiquimod Mouse Model

    by Ina Suhrkamp, Peter J. Morrison, Julian C. Assmann, Markus Schwaninger, Nina Wettschureck, Ulrich Mrowietz


  • Open Access

    Oral dimethyl fumarate induces changes within the peripheral neutrophil compartment of patients with psoriasis that are linked with skin improvement*

    by P.J. Morrison, I. Suhrkamp, S. Gerdes, U. Mrowietz

    Background Dimethyl fumarate (DMF) is a treatment for moderate‐to‐severe psoriasis and multiple sclerosis. DMF therapy typically improves skin inflammation within the first 3 months of treatment. DMF is a prodrug that generates the hydroxycarboxylic acid receptor 2 (HCA2) agonist, monomethyl fumarate (MMF). Despite widespread clinical use, DMF’s mechanism of action is not fully understood. Objectives We wished to characterize the changes induced by DMF in peripheral neutrophils within the 3 months of treatment to better understand its early anti‐psoriatic effects. Methods Flow cytometry was used to assess T cell and neutrophil frequencies, apoptosis and activation phenotype. In vitro culture of neutrophils with DMF and MMF was used to evaluate apoptosis and HCA2 internalisation. Serum levels of neutrophil degranulation products were measured by ELISA. Results Baseline psoriasis patients had significantly higher leukocyte counts compared to controls, with a large population of pro‐inflammatory CD62LloCD11bbright neutrophils. Analysis revealed that DMF treatment reduced the frequency of CD62LloCD11bbright neutrophils and serum levels of neutrophil activation markers. This reduction was not linked to increased apoptosis. Conclusions Our results reveal a novel in vivo effect of DMF therapy on pro‐inflammatory neutrophils that likely contributes to this treatment’s anti‐psoriatic efficacy.


  • The Pharmacokinetics of Fumaric Acid Esters Reveal Their In Vivo Effects

    by Ulrich Mrowietz, Peter John Morrison, Ina Suhrkamp, Margaret Kumanova, Bernd Clement


  • Differential Requirements for IL-17A and IL-22 in Cecal versus Colonic Inflammation Induced by Helicobacter hepaticus

    by Peter J. Morrison, Sarah J. Ballantyne, Sandy J. Macdonald, John W.J. Moore, David Jenkins, Jill F. Wright, Lynette A. Fouser, Marika C. Kullberg


  • IL-22 Fate Reporter Reveals Origin and Control of IL-22 Production in Homeostasis and Infection

    by Helena Ahlfors, Peter J. Morrison, João H. Duarte, Ying Li, Judit Biro, Mauro Tolaini, Paola Di Meglio, Alexandre J. Potocnik, Brigitta Stockinger

    IL-22 is a cytokine that regulates tissue homeostasis at barrier surfaces. A variety of IL-22–producing cell types is known, but identification on the single-cell level remains difficult. Therefore, we generated a fate reporter mouse that would allow the identification of IL-22–producing cells and their fate mapping in vivo. To trace IL-22–expressing cells, a sequence encoding Cre recombinase was cloned into the Il22 locus, and IL22Cre mice were crossed with reporter mice expressing enhanced yellow fluorescence protein (eYFP) under control of the endogenous Rosa26 promoter. In IL22CreR26ReYFP mice, the fluorescent reporter permanently labels cells that have switched on Il22 expression, irrespective of cytokine production. Despite a degree of underreporting, eYFP expression was detectable in nonimmune mice and restricted to group 3 innate lymphoid cells (ILC3) in the gut and γδ T cells in skin or lung. Upon skin challenge with imiquimod, eYFP+ γδ and CD4 T cells expanded in the skin. Infection with Citrobacter rodentium initially was controlled by ILC3, followed by expansion of eYFP+ CD4 T cells, which were induced in innate lymphoid follicles in the colon. No eYFP expression was detected in small intestinal Th17 cells, and they did not expand in the immune response. Colonic eYFP+ CD4 T cells exhibited plasticity during infection with expression of additional cytokines, in contrast to ILC3, which remained largely stable. Single-cell quantitative PCR analysis of eYFP+ CD4 T cells confirmed their heterogeneity, suggesting that IL-22 expression is not confined to particular subsets or a dedicated Th22 subset.


  • Open Access

    IL-9–mediated survival of type 2 innate lymphoid cells promotes damage control in helminth-induced lung inflammation

    by Jan-Eric Turner, Peter J. Morrison, Christoph Wilhelm, Mark Wilson, Helena Ahlfors, Jean-Christophe Renauld, Ulf Panzer, Helena Helmby, Brigitta Stockinger

    IL-9 fate reporter mice established type 2 innate lymphoid cells (ILC2s) as major producers of this cytokine in vivo. Here we focus on the role of IL-9 and ILC2s during the lung stage of infection with Nippostrongylus brasiliensis, which results in substantial tissue damage. IL-9 receptor (IL-9R)–deficient mice displayed reduced numbers of ILC2s in the lung after infection, resulting in impaired IL-5, IL-13, and amphiregulin levels, despite undiminished numbers of Th2 cells. As a consequence, the restoration of tissue integrity and lung function was strongly impaired in the absence of IL-9 signaling. ILC2s, in contrast to Th2 cells, expressed high levels of the IL-9R, and IL-9 signaling was crucial for the survival of activated ILC2s in vitro. Furthermore, ILC2s in the lungs of infected mice required the IL-9R to up-regulate the antiapoptotic protein BCL-3 in vivo. This highlights a unique role for IL-9 as an autocrine amplifier of ILC2 function, promoting tissue repair in the recovery phase after helminth-induced lung inflammation.


  • Open Access

    Th17-cell plasticity in Helicobacter hepaticus–induced intestinal inflammation

    by P J Morrison, D Bending, L A Fouser, J F Wright, B Stockinger, A Cooke, M C Kullberg


  • Open Access

    Interleukin-23 and T helper 17-type responses in intestinal inflammation: from cytokines to T-cell plasticity

    by Peter J. Morrison, Sarah J. Ballantyne, Marika C. Kullberg

    Interleukin-23 (IL-23) plays an essential role in driving intestinal pathology in experimental models of both T-cell-dependent and innate colitis. Furthermore, genome-wide association studies have identified several single-nucleotide polymorphisms in the IL-23 receptor (IL-23R) gene that are associated with either susceptibility or resistance to inflammatory bowel disease in humans. Although initially found to support the expansion and maintenance of CD4(+) T helper 17 (Th17) cells, IL-23 is now recognized as having multiple effects on the immune response, including restraining Foxp3(+) regulatory T-cell activity and inducing the expression of Th17-type cytokines from non-T-cell sources. Here we focus on Th17 cells and their associated cytokines IL-17A, IL-17F, IL-21 and IL-22. We review studies performed in mouse models of colitis where these effector cytokines have been shown to have either a pathogenic or a tissue-protective function. We also discuss the heterogeneity found within the Th17 population and the phenomenon of plasticity of Th17 cells, in particular the ability of these lymphocytes to extinguish IL-17 expression and turn on interferon-γ production to become Th1-like 'ex-Th17' cells. Interleukin-23 has been identified as a key driver in this process, and this may be an additional mechanism by which IL-23 promotes pathology in the intestinal tract. These 'ex-Th17' cells may contribute to disease pathogenesis through their secretion of pro-inflammatory mediators.